Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
Lung cancer is a deadly disease with high mortality and morbidity. Most cases of lung cancer are due to non-small cell carcinoma, with 16% of cases being small cell carcinoma. The biology at a cellular level is of interest at many levels. Knowing cellular pathways helps to further enhance our knowle...
Saved in:
Main Authors: | Evan Pisick, Simha Jagadeesh, Ravi Salgia |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2004-01-01
|
Series: | The Scientific World Journal |
Online Access: | http://dx.doi.org/10.1100/tsw.2004.117 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Patients outcomes in lung adenocarcinoma transforming to small-cell lung cancer after tyrosine kinase inhibitor therapy
by: Shuai Wang, et al.
Published: (2025-02-01) -
Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
by: Soomin Kim, et al.
Published: (2025-02-01) -
Protein tyrosine kinase but not protein kinase C inhibition blocks receptor induced alveolar macrophage activation
by: K. Pollock, et al.
Published: (1993-01-01) -
Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors in Advanced Nonsmall Cell Lung Cancer Patients
by: Yan-Jei Tang, et al.
Published: (2024-01-01) -
Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study
by: Chenming Liu, et al.
Published: (2025-02-01)